Loading...
|
Please use this identifier to cite or link to this item:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/23646
|
Title: | Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy |
Authors: | Chang, YT;Chung, MC;Hsieh, CC;Shieh, JJ;Wu, MJ |
Keywords: | diabetic nephropathy;epithelial-mesenchymal transition;protocatechuic aldehyde |
Date: | 2021 |
Issue Date: | 2022-08-05T09:40:38Z (UTC)
|
Publisher: | MDPI |
Abstract: | Diabetic nephropathy (DN) is one of the most severe chronic kidney diseases in diabetes and is the main cause of end-stage renal disease (ESRD). Protocatechuic aldehyde (PCA) is a natural product with a variety of effects on pulmonary fibrosis. In this study, we examined the effects of PCA in C57BL/KS db/db male mice. Kidney morphology, renal function indicators, and Western blot, immunohistochemistry, and hematoxylin and eosin (H&E) staining data were analyzed. The results revealed that treatment with PCA could reduce diabetic-induced renal dysfunction, as indicated by the urine albumin-to-creatinine ratio (db/m: 120.1 +/- 46.1 mu g/mg, db/db: 453.8 +/- 78.7 mu g/mg, db/db + 30 mg/kg PCA: 196.6 +/- 52.9 mu g/mg, db/db + 60 mg/kg PCA: 163.3 +/- 24.6 mu g/mg, p < 0.001). However, PCA did not decrease body weight, fasting plasma glucose, or food and water intake in db/db mice. H&E staining data revealed that PCA reduced glomerular size in db/db mice (db/m: 3506.3 +/- 789.3 mu m(2), db/db: 6538.5 +/- 1818.6 mu m(2), db/db + 30 mg/kg PCA: 4916.9 +/- 1149.6 mu m(2), db/db + 60 mg/kg PCA: 4160.4 +/- 1186.5 mu m(2) p < 0.001). Western blot and immunohistochemistry staining indicated that PCA restored the normal levels of diabetes-induced fibrosis markers, such as transforming growth factor-beta (TGF-beta) and type IV collagen. Similar results were observed for epithelial-mesenchymal transition-related markers, including fibronectin, E-cadherin, and alpha-smooth muscle actin (alpha-SMA). PCA also decreased oxidative stress and inflammation in the kidney of db/db mice. This research provides a foundation for using PCA as an alternative therapy for DN in the future. |
URI: | http://dx.doi.org/10.3390/toxins13080560 https://www.webofscience.com/wos/woscc/full-record/WOS:000690090700001 https://ir.csmu.edu.tw:8080/handle/310902500/23646 |
Relation: | TOXINS ,2021,v13,issue 8 |
Appears in Collections: | [researcher portal] Artical
|
Files in This Item:
File |
Description |
Size | Format | |
index.html | | 0Kb | HTML | 237 | View/Open |
|
All items in CSMUIR are protected by copyright, with all rights reserved.
|